---
title: "Haisen Pharm released its 2024 annual performance, with a net profit attributable to the parent company of 123 million yuan, an increase of 17.09%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233484070.md"
description: "Haisen Pharm released its 2024 annual report, with operating revenue of 472 million yuan, a year-on-year increase of 18.63%; net profit attributable to the parent company was 123 million yuan, a year-on-year increase of 17.09%. The net profit excluding non-recurring gains and losses was 117 million yuan, a year-on-year increase of 15.02%. Basic earnings per share were 1.22 yuan, with a proposed cash dividend of 1.70 yuan for every 10 shares, and a bonus issue of 4.8 shares. All business segments achieved sales growth, with raw materials, intermediates, and formulations increasing by 16.74%, 35.51%, and 45.82%, respectively"
datetime: "2025-03-27T15:01:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233484070.md)
  - [en](https://longbridge.com/en/news/233484070.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233484070.md)
---

# Haisen Pharm released its 2024 annual performance, with a net profit attributable to the parent company of 123 million yuan, an increase of 17.09%

According to the Zhitong Finance APP, Haisen Pharm (001367.SZ) released its annual report for 2024, reporting an operating income of 472 million yuan, a year-on-year increase of 18.63%. The net profit attributable to shareholders of the listed company was 123 million yuan, a year-on-year increase of 17.09%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 117 million yuan, a year-on-year increase of 15.02%. The basic earnings per share were 1.22 yuan. In addition, it plans to distribute a cash dividend of 1.70 yuan (including tax) for every 10 shares to all shareholders and to convert 4.8 shares for every 10 shares from the capital reserve to all shareholders.

During the reporting period, the company's business segments, including raw materials, intermediates, and formulations, all made significant progress, with sales growth rates of 16.74%, 35.51%, and 45.82%, respectively

### Related Stocks

- [001367.CN](https://longbridge.com/en/quote/001367.CN.md)

## Related News & Research

- [Tourist arrivals up 10% year on year in April, driven by Hong Kong Sevens](https://longbridge.com/en/news/286512798.md)
- [BPCL plans ₹25,000 crore capex for FY27, calls fuel price hike respite](https://longbridge.com/en/news/286942050.md)
- [AI is not replacing workers on a large scale so far, says Bank of Canada](https://longbridge.com/en/news/286540351.md)
- [PTA-DD: Warimpex Finanz- und Beteiligungs AG: Managers' transactions announcement according to article 19 MAR](https://longbridge.com/en/news/286901864.md)
- [Valhalla Metals Announces Closing of First Tranche of Over-Subscribed Private Placement | VMXXF Stock News](https://longbridge.com/en/news/286904505.md)